AUG 14, 2018 11:40 PM PDT

Using Arsenic to Enhance Cancer Therapies Beyond Leukemia

WRITTEN BY: Mauri Brueggeman

Arsenic is anecdotally known to many as a poison, but it has historically been a potent chemotherapy agent.  Chemotherapies are basically controlled poisons; it is not so far-fetched to think of arsenic in these terms.  Originally used to treat leukemia in the nineteenth century, known as Fowler’s solution, arsenic continues to be investigated and used in conjunction with all-trans retinoic acid (ATRA) for the treatment and cure of Acute Promyelocytic Leukemia (APL).  Specifically, arsenic trioxide (ATO) is the active component needed to promote the anti-leukemic process in the body.  ATO acts on APL by destroying the main fusion protein called PML-RARα which is the disease driving genetic change causing the arrest of myelocytic cell differentiation.  Myelocytic cells need retinoic acid, or vitamin A, to continue developing into mature neutrophils which is why ATRA was used in the first place. 

A recent study published in Nature Communications outlines how ATO and ATRA together target an oncogenic signaling regulator called Pin1.  Pin1 activity is documented in multiple cancers besides leukemia including breast and liver solid tumors.  ATO has been found to degrade Pin1 and ATRA controls the cell’s ability to take up ATO when it is in the body.    

This is an emerging area of research because solid tumors are challenging to target; tumors are often found to utilize multiple activation pathways to remain viable and support their rapid growth.  Blocking one pathway may not work but finding the target that drives a multitude of signaling mechanisms, like in the case of Pin1, provides promise.  ATO and ATRA together have been proven safe at clinical doses and inhibited triple negative breast cancer cells as well as other tumor initiating cells in animal models. 

In vivo studies and clinically relevant data have demonstrated the viability and efficacy of using arsenic in conjunction with other therapeutic agents, like in the case of ATO-ATRA and APL.  Because this combination was found to impede further tumor growth via tumor initiating cells, the tumor’s normal renewal and progression process is disrupted.  In fact, the authors found that Pin1 is “highly enriched” in breast tumor initiating cells and propose further study on whether Pin1 inhibitor drugs could target these specific breast tumor cells.

Sources: Nature Communications, Pathology Outlines, Nature Medicine, Journals of Hematology & Oncology,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
NOV 15, 2019
Cancer
NOV 15, 2019
An astronaut's training for cancer patients
The comparison is perhaps unexpected, but the findings show potential: astronauts experience similar physical stress in spaceflight as cancer patients rece...
NOV 21, 2019
Cancer
NOV 21, 2019
Inhalable nanoparticle-immunotherapy provides new hope for lung cancer
New research published in Nature Communications details the results of a study that tested inhalable nanoparticle-immunotherapy to determine its impact on ...
DEC 18, 2019
Genetics & Genomics
DEC 18, 2019
Learning More About The Genetic Adaptations Cancer Relies On
Cancer cells can adapt to mutations in the genome that might kill the cells by altering the activity of their genes....
JAN 20, 2020
Genetics & Genomics
JAN 20, 2020
Epigenetic Changes Make Breast Cancer Cells Drug Resistant
Researchers have found that changes in the structure of the genome in breast cancer cells can make them resistant to drug therapies....
JAN 20, 2020
Technology
JAN 20, 2020
Open-Source Software Judges The Accuracy of Cancer Predicting Computer Programs
Cancers are generally composed of diverse cells that vary in genetics—these variations often make a particular cancer more susceptible or resistant t...
FEB 16, 2020
Cell & Molecular Biology
FEB 16, 2020
Growing Cells on Scaffolding as an Alternative to Animal Models
Researchers may have just made it easier for investigators to switch to an engineered model and replace their animal colonies with electrospun synthetics....
Loading Comments...